To explore the complexities of pain in rheumatoid arthritis (RA) and osteoarthritis (OA), highlighting the roles of neuropathic and nociplastic pain alongside traditional nociceptive pain, and emphasizing the significance of understanding these mechanisms for improved treatment.
Key Findings:
In RA, median swollen joint counts decreased from 12 in 1985 to 0 by 2021-2022, yet median pain VNS scores remained at 5, indicating persistent pain despite reduced inflammation.
In OA, pain VAS/VNS scores were consistently between 4 to 6 from 1979 to 2022, suggesting stable pain levels over decades.
RAPID3 scores showed no significant change in RA and OA from 1985 to 2022, indicating a need for further investigation into factors influencing these scores.
Patients with RA or OA who screened positive for anxiety, depression, and/or fibromyalgia reported significantly higher pain scores, underscoring the impact of these comorbidities.
Interpretation:
The findings suggest that pain in RA and OA may not solely be due to nociceptive factors, indicating the need for a broader understanding of pain mechanisms, including nociplastic pain, which could inform treatment strategies.
Limitations:
The study is hypothesis-generating rather than hypothesis-testing, limiting the ability to draw definitive conclusions.
Routine care often lacks formal screening for comorbidities like anxiety and depression, which may lead to underreported pain levels and inadequate treatment.
Conclusion:
Further investigation into nociplastic pain in rheumatic diseases could enhance understanding and treatment of musculoskeletal pain, particularly in identifying effective interventions for patients with comorbid conditions.
